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Objectives Buffered low-dose sublingual transmucosal zolpidem lozenge hemitartrate (ST zolpidem) is being developed for
the treatment of middle-of-the-night insomnia. The objective of this double-blind placebo-controlled cross-over study (n¼24)
was to evaluate the pharmacokinetics (PK) and daytime-sedative proﬁle of 1.0, 1.75, and 3.5mg dose of the formulation.
Methods Daytime sedation was measured pre-dose and up to 5h post-dose objectively by the Digit Symbol Substitution
Test(DSST)andsubjectivelyusingtheVisualAnalogScale(VAS).BloodsamplesforPKassessmentwascollectedpre-dose
and up to 12h post-dose.
Results The 1.75 and 3.5mg, but not the 1mg, ST zolpidem produced signiﬁcant sedationversus placebowithin 20min of
dosing which lasted for up to 3h. Zolpidem from the formulation was rapidly absorbed and reached maximum plasma
concentrations within 38min of dosing, however the half-life was independent of the dose and side effects were consistent
with the known pharmacology of the drug.
Conclusions ST zolpidem produced rapid, short duration of sedation and the effect was consistent with its PK proﬁle. This
novel low-dose formulation of zolpidem may provide clinicians and patients with a prn option for the management of sleep
maintenance insomnia. Copyright # 2007 John Wiley & Sons, Ltd.
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INTRODUCTION
Zolpidem is extensively prescribed as a hypnotic in
clinical practice, both in the form of a standard oral
tablet (Ambien
1) and a controlled-release tablet
(Rosenberg, 2006; Soubrane et al., 2005). In either
case, it is to be ingested at bedtime with an available
7–8h of time in bed because of its potential for
next-morning residual effects on memory and
psychomotor performance following shorter periods
of bedtime (Partinen et al., 2003; Verster et al., 2002).
A different, low-dose sublingual transmucosal for-
mulation of zolpidem (ST zolpidem, Intermezzo
TM)i s
currently under investigation as a sedative-hypnotic
with rapid onset and short duration of action for the
treatment of insomnia patients whose primary
complaint is difﬁculty returning to sleep after
middle-of-the-night awakening (Roth et al., 2006).
This formulation consists of sublingual lozenges
designed for transmucosal delivery of zolpidem.
Thepurposeofthis studywas toevaluate,inhealthy
volunteers after daytime administration, the pharma-
codynamic (PD) and pharmacokinetic (PK) proﬁles
and tolerability of ST zolpidem lozenges compared to
placebo.
METHODS
Study design
This study was a single-dose, randomized, double-
blind, placebo-controlled, daytime, cross-over study.
Three doses of ST zolpidem (1.0, 1.75, and 3.5mg)
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Accepted 30 July 2007were compared with matching placebo in healthy
volunteers. The protocol for this study was approved
by an institutional review board for the study site and
the study itself was conducted in accordance with the
DeclarationofHelsinkiandtheGoodClinicalPractice
guidelines. Subjects were paid for their participation.
Subject selection included a clinical assessment
visit and 7 days of morning sleep diary screening to
ensure that all study criteria were met. Subjects were
randomized to one of four treatment sequences, which
included all three doses of active treatment and
placebo. Each treatment period consisted of 2 days
separated by a washout period of 5–12 days.
During each of the four treatment periods, subjects
wereadmittedtothesiteontheeveningpriortodosing
and had an obligatory 8h in bed. The following two
mornings, subjects were awakened at a ﬁxed time and,
following baseline assessments, received the study
drug at 8:00 AM (approximately 1h after awakening).
PD assessments were conducted prior to dosing and
over a period of 5h after study drug administration on
the ﬁrst morning of treatment. On the secondmorning,
the same treatment was administered and venous
blood was drawn prior to dosing and over a period of
12h following study treatment administration for PK
evaluation.
In each treatment period, subject mobility was
limited. Speciﬁcally, for the ﬁrst 5h after dose
administration, participants were required to remain
seated unless medically or procedurally necessary.
Furthermore, subjects were kept awake until all
procedures were completed. Subjects had to pass a
heel-to-toe gait test prior to leaving the laboratory.
Subject recruitment and selection
Healthy, non-smoking adult men and women, aged
21–44 with no current self-reported sleeping problems
were eligible for participation in the study. After
signing a written informed consent statement and follow-
ing initial screening, a physical examination, clinical
laboratory tests, and electrocardiogram, subjects were
invited to complete a 7-day sleep diary provided that
they did not (1) have any DSM-IVAxis I psychiatric
disorders or any circadian rhythm sleep disorder, (2)
have a history of substance abuse or substance
dependence, (3) have a Epworth Sleepiness Scale
score of greater than 12, (4) have had an acute
clinically signiﬁcant illness or surgery, including oral
surgery, tooth extraction, or piercing of the lip/tongue
within 60 days prior to Day 1 of the study, (5) utilize
any over-the-counter or prescription medication within
2 weeks prior to screening, or (6) take any drugs
known to induce or inhibit hepatic drug metabolism
within 30 days prior to Day 1 of double-blind study
medication.
Subjects qualiﬁed for randomization if their diaries
reported a mean weekly latency to sleep onset of
 30min, a mean weekly total time in bed of  7h, and
a stable bedtime pattern as deﬁned by a usual bedtime
between 2200 and 2400 and a usual rise time between
0500 and 0800 (neither of which varied by more than
2h on 5 of 7 nights).
Study procedures
Study drug. The four treatments evaluated were 1.0,
1.75, and 3.5mg ST zolpidem and placebo lozenges.
Subjects were randomized into dosing sequences of
four treatment periods (Latin Square) that were
separated by 5–12 days. Each subject was randomized
into a dosing sequence that included all four treat-
ments. Medication was dispensed by study personnel
on each morning in the sleep laboratory at 8 AM.
Subjects were instructed to rinse their mouth with
water prior to dosing and then place the lozenge under
their tongue until it dissolved. Saliva was swallowed
every 2min until the nearest 2min after complete
lozenge dissolution. Study personnel performed oral
cavity examinations before and after dosing to ensure
consumption of medication and to note any signs of
oral irritation.
PD assessments. Subjects practiced PD tests after
admission to the laboratory on the night prior to
treatment. On the ﬁrst morning of each treatment
period, subjects performed the PD tests immediately
beforedosingandat10min[visualanalogscale(VAS)
only],20min, 1, 1.5, 2, 2.5, 3, 4, and 5h post-dose. PD
tests were always performed in the same order: Digit
Symbol Substitution Test (DSST), Choice Reaction
Test (CRT), Symbol Copying Test (SCT), subject
rating of sedation (VAS) and Word Recall Test.
During the DSST (Kaplan et al., 1997), subjects
were given a set of symbols with corresponding single
digit numbers and a set of ‘blank’ boxes with
corresponding digits. Subjects were asked to make
as many symbol-for-digit substitutions as possible
working from left to right without skipping any boxes
within a 90-s period and the number of correct
substitutions was recorded. Throughout the study,
subjects completed equivalent DSST variants, with no
individual taking the same form more than once.
For the CRT (Roehrs et al., 1994), subjects were
provided with a hand-held device with response
buttons for measuring reaction time following the
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time was deﬁned as the time in milliseconds between
the onset of the stimulus and the response buttonbeing
pressed. The mean response time, the number of
errors, and the number of lapses (deﬁned as reaction
time >500ms) were evaluated.
During the SCT (Stone, 1984), subjects were given
a sheet ﬁlled with double rows: the upper row ﬁlled
with symbols, the lower row empty. Subjects were
asked to make as many accurate symbol-copies as
possible working from left to right without skipping
any boxes within a 90-s period and the number of
correct copies was recorded. Throughout the study,
subjects completed equivalent SCT variants, with no
individual taking the same form more than once.
Finally, acquisition and immediate recall of
information was evaluated using a word-list free
recall procedure (Shader et al., 1986). Fifteen words
were read in random order at a rate of one word per
second, during each test session. Recall was tested
immediately after presentation of the list, and subjects
were given 1min to write down list items recalled in
any order. Throughout the study, subjects had to recall
equivalent word-list variants, with no individual
hearing the same list more than once. The number
of correct words (ignoring spelling mistakes) was
recorded.
Subjective ratings. Subjects’ self-ratings of sedative
effects were obtained on a 100mm VAS anchored by
‘0’¼‘very sleepy’ and 100’¼‘wide awake and alert’.
This type of VAS scale is often used in clinical trials to
assay sedative effects (typically as residual effects in
the morning).
PK sample collection and parameters. On the second
morning of the treatment period, a total of 18 blood
sampleswere collected.The ﬁrstsamplewas collected
prior to dosing. Subsequent samples were collected at
5, 10, 20, 30, and 45min and 1, 1.5, 2, 2.5, 3, 3.5, 4, 5,
6, 8, 10, and 12h post-dose. All blood samples were
centrifuged within 10min and plasma was separated,
divided into two duplicate aliquots, and frozen until
the time of assay. The bioanalytical laboratory analy-
zed zolpidem in plasma samples using a validated LC/
MS/MS method. PK parameters included the area
under the plasma concentration curve from time 0 to
the last measurable concentration (AUC0-t), the area
under the plasma concentration curve from time 0 to
inﬁnity (AUC0-inf), the maximum plasma concen-
tration (Cmax), the time of the maximum plasma
concentration (tmax), and the apparent terminal
elimination half-life (t1/2).
Safety evaluations
Vital signs were recorded at screening, prior to dosing
and at scheduled intervals during each treatment
period. Subjects oral cavities were examined for
buccal irritation prior to dosing, at the time of lozenge
dissolution,at15,30,60,and 120minpost-dissolution
and at discharge. A physical examination along with
chemistry,hematology, and urinalysis were performed
at study entry and prior to discharge in the fourth
treatment period. All subjects had to pass a heel-to-toe
gait test before leaving the clinic.
Statistical analysis
Allanalysesperformedinthisstudyweredeﬁnedprior
to breaking the study blind. All randomized subjects
completed all four treatment periods. Therefore, the
intent-to-treat and per-protocol populations were
identical. The statistical analyses discussed reﬂect
the full set of 24 randomized patients.
PD values are presented and analyzed as change
relative to pre-dose values. Each time point was
evaluated separately relative to the baseline value. In
addition,area underthe time-effectcurveforthe effect
change scores was calculated for deﬁned time
intervals.
PK parameters were calculated from the concen-
tration–time data using non-compartmental tech-
niques. Using SAS, ANOVA was performed on
untransformed tmax and t1/2, and on ln-transformed
dose normalized values of AUC0-t,A U C 0-inf, and Cmax
at the alpha level of 0.05. Linearity in PK response of
various doses was assessed by applying the power
function P¼A
 Dose
b to non-normalized Cmax and
AUC0-t values of zolpidem.
Safety was assessed by adverse events (AEs), vital
signs, and laboratory parameters. AEs were deﬁned
according to the Medical Dictionary for Regulatory
Activities (MedDRA
1). AEs with onset (or worsen-
ing) after the start of study drug were considered
treatment-emergent. The frequency of treatment-
emergent AEs and the frequency of events by body
system were summarized by treatment period accord-
ing to preferred term and system organ class.
RESULTS
Demographics
A total of 24 subjects were randomized to treatment
for this study. All participants completed all four
treatmentperiods; therewere no discontinuations. The
demographics and sleep histories of the subject
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seen, study subjects were healthy and reported no
sleep difﬁculties.
Psychomotor performance
The sedative effects of ST zolpidem lozenges were
assessed by multiple PD evaluations, including DSST,
CRT, SCT, and Word Recall as well as by subjective
self-rating of sedation by VAS. On the pre-drug
performance sessions, no signiﬁcant treatment differ-
enceswereobservedonanyoftheseendpoints.During
post-drug performance, in comparison to placebo, all
measures were signiﬁcantly affected by at least one
dose of ST zolpidem.
DSST scores at individual time points indicated
signiﬁcant psychomotor impairment by ST zolpidem
3.5 and 1.75mg as early as 20min post-intake
(Figure 1). Signiﬁcant reduction in DSST scores
lasted up to 90min post-dose (3.5mg), and perform-
ance after ST zolpidem was no longer distinguishable
from placebo on any endpoint as early as at the 3h
time point. These observations were conﬁrmed by
partial 1h effect-area measures (Figure 2). There was
signiﬁcant impairment compared to placebo for ST
zolpidem 1.75mg and 3.5mg during the (0–1)h time
period, while there was no longer any difference
during the (4–5)h time period. ST zolpidem 1mg had
no measurable effect by either analysis.
Table 1. Subject demographics
Gender
Male (%) 13 (54.2)
Female (%) 11 (45.8)
Race
Caucasian (%) 15 (62.5)
African-American (%) 9 (32.5)
Age
Mean (SD) 34.7 (7.1)
Range 21–44
Weight (kg)
Mean (SD) 74.4 (10.8)
Range 51.7–100.2
BMI
Mean (SD) 24.9 (2.8)
Range 19–30
Table 2. Subject sleep history
Usual time in bed (h)
Mean (SD) 8.2 (0.4)
Range 8.0–9.0
Usual time to fall asleep (min)
Mean (SD) 13.0 (5.4)
Range 3.0–25.0
Usual sleep time during night (h)
Mean (SD) 8.1 (0.4)
Range 7.5–9.0
Usual time awake during night (min)
Mean (SD) 2.3 (2.8)
Range 0.0–10.0
Usual number of nocturnal awakenings
01 3
11 0
21
Epworth sleepiness scale
Mean (SD) 3.5 (2.6)
Range 0.0–11.0
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Figure 1. Mean change over baseline in DSST scores
Figure 2. Mean SEM 1h effect areas for changes over baseline
in DSST scores
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are summarized in Table 3. Overall, it is readily
apparent that ST zolpidem at the 1mg dose has no
measurable effect on any parameter (except at one
time point measuring the number of errors in CRT),
whereas ST zolpidem 3.5mg impacts all outcome
measures, albeit for different time periods. Based
on these tests, the time of maximum impairment
by ST zolpidem 1.75 and 3.5mg ranges from 20min
to 2h post-dose, and time post-drug where the
measured parameters no longer differed from placebo
after 2h.
Speciﬁcally, onset of impairment of CRTwas found
to be as early as the other PD outcomes, but duration
was differentially affected depending on the speciﬁc
parameter. Actual reaction time was signiﬁcantly
prolonged by zolpidem 3.5mg at the early time points
only and was no longer different from placebo at 2h
post-drug administration. The number of lapses was
affected by both 3.5 and 1.75mg ST zolpidem, with
peak effect for both at 20min, but duration of
impairmentwas longerforthe 3.5mgthan the 1.75mg
dose, 2.5h, and 1.0h, respectively. The number of
errors committed during CRT measures was found to
besomewhatvariable. The3.5mgdosewas associated
with the longest duration of impairment with a peak
effect at 3h and subsequently, no statistical difference
fromplacebo at4h.Althoughthe1.75mgdosedidnot
differ at any time point from placebo, there was one
statistically signiﬁcant increase in the number of
errors after the 1mg dose, occurring at the 1h time
point (Table 3).
The two higher doses of ST zolpidem, that is, 3.5
and 1.75mg, signiﬁcantly impaired ﬁne motor activity
as measured by SCT, with impairment due to the
higher dose lasting 30min longer than the lower, 1.5h
versus 1h, respectively (Table 3).
Lastly, in terms of memory, compared to placebo,
immediate free recall was signiﬁcantly impaired by
ST zolpidem 3.5mg at 20min post-ingestion and this
effect was no longer detectable 1h later. No
measurable effect was observed with the two lower
doses of ST zolpidem (Table 3).
Subjective ratings
Self-ratings of sedation by the VAS exhibited a pattern
similar to that observed for DSST (Figure 3). Subjects
did not feel sedated at 10min post-drug intake, but
Table 3. Effect of ST zolpidem on daytime PD assessments
Parameter
ST zolpidem
dosage (mg)
Maximum change
relative to placebo p-value
Time of
maximum change
Time no longer
different from placebo
Word Recall (# words) 3.5 1.2 0.0387 20min 1h
1.75 1.0 N.S. 1h, 2h N.A.
1.0 0.6 N.S. 1h N.A.
CRT (reaction time, ms) 3.5 234.7 <0.0001 20min 2h
1.75 103.3 N.S. 1h N.A.
1.0 85.7 N.S. 1h N.A.
CRT (# lapses) 3.5 13.6 <0.0001 20min 2.5h
1.75 5.6 0.0199 20min 1h
1.0 4.3 N.S. 1h N.A.
CRT (# errors) 3.5 5.1 0.0225 3h 4h
1.75 3.1 N.S. 2.5h N.A.
1.0 6.8 0.0419 1h 1.5h
SCT 3.5 14.8 <0.0001 20min 2.0h
1.75 7.6 0.0011 1h 1.5h
1.0 3.0 N.S. 1h N.A.
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Figure 3. Mean change over baseline in scores of self-rated
sedation on 100mm VAS
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placebo from 20min through 2h post-drug at the 1.75
and 3.5mg dose levels. The ratings remained different
from placebo for up to 3h, but were no longer
statistically signiﬁcantly different, primarily due to
progressively increased sedation rating in the placebo
condition.
PK
Descriptive statistics for the PK parameters are
presented by dose in Table 4. Over the dose range
and time periods studied, mean Cmax and mean AUC
values were proportional to dose. Mean tmax and mean
elimination half-life were equivalent across treatment
conditions. Plasma concentration–time proﬁles fol-
lowing ST zolpidem administration are presented in
Figure 4. Zolpidem plasma levels of >20–25ng/ml
were reached within 20min after both 1.75 and 3.5mg
ST zolpidem administration and were maintained for
upto4h.Zolpidem wasno longerdetectable12hafter
administration.
Safety
The ST zolpidem lozenges were generally safe and
well tolerated. Subjects experienced a total of 48 AEs,
most of which were related to the clinical effect of the
drug sedation and were mild-to-moderate in severity
(Table 5). Side effects appeared only at the high dose,
with 10 subjects reporting sedation at 3.5mg
compared to 3 subjects for placebo. Dizziness, nausea,
and headache peaked at the 3.5mg dose level (three,
three and two subjects, respectively), with fewer
instances seen with the 1.75mg dose (one, zero, and
two subjects) and no reports of these conditions at
either the 1.0mg level or placebo. Only one event
(epigastric pain) was severe and was judged unrelated
to treatment (1.75mg lozenge) by the investigator.
Two AEs not related to treatment (headache: 1.75mg
lozenge, dysmenorrhoea: placebo) were treated with
Tylenol or ibuprofen. All other events resolved
without treatment.
DISCUSSION
Middle-of-the-night awakening with difﬁculty return-
ing to sleep is a common complaint in chronic
insomnia patients (Shochat et al., 1999). According to
the National Sleep Foundation’s 1995 ‘Sleep in
America’ poll, about 20% of the US population
may be suffering from MOTN insomnia and the
prevalence in primary care patients may be even
higher (Hohagen et al., 1994a, 1994b; Mellingeret al.,
1985).Manypatients with thiskindofinsomniadonot
experience MOTN awakenings every night, but may
dosethemselvesprophylacticallywithahypnoticeach
evening prior to sleep, since presently all approved
sedativehypnoticsareindicated forpre-sleep useonly.
Ideally, however, MOTN sleep disruptions should be
managed by MOTN dosing, only when the symptoms
occur. A sedative-hypnotic with rapid onset and
short duration would be ideal for such treatment.
Low-dose, transmucosal zolpidem (ST zolpidem) is
being developed to provide clinicians and patients
with such an option for the management of MOTN
insomnia. The present study evaluated, in healthy
volunteers, the PD/PKof single doses of 1.0, 1.75, and
3.5mg ST zolpidem following daytime adminis-
tration.
Table 4. Mean PK parameters (SD) of ST zolpidem
1.0mg 1.75mg 3.5mg
Cmax (ng/ml) 17.03 (6.84) 32.17 (10.38) 64.14 (22.36)
Range Cmax 0–35.51 9.33–60.33 19.85–125.96
t1/2 (h) 2.33 (0.79) 2.43 (0.60) 2.45 (0.58)
AUC0-inf (ng
 h/ml) 66.16 (31.49) 126.10 (53.39) 242.57 (100.37)
tmax (min) 35.7 (12.7) 37.9 (16.1) 37.9 (12.3)
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Figure 4. Plasma concentration–time proﬁles of zolpidem follow-
ing ST zolpidem administration
Table 5. AEs occurring in  5% of subjects
Variable Placebo 1.0mg 1.75mg 3.5mg
Somnolence 3 (12.5%) 5 (20.8%) 3 (12.5%) 10 (41.7%)
Fatigue 6 (25.0) 2 (8.3) 8 (33.3) 4 (16.7)
Dizziness — — 1 (4.2) 3 (12.5)
Nausea — — — 3 (12.5)
Headache — — 1 (4.2) 2 (8.3)
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Choice Reaction Time,SCT,WordRecall, andscoring
on a self-rating 100mm VAS of sedation, all of which
have been used extensively for the evaluation of the
immediate performance-disruptive effects of sedative-
hypnotic drugs (Greenblatt et al., 1998) or their
morning residual effects following their bedtime
administration (Piergies et al., 1996; Scharf et al.,
1994).
It is noteworthy that this study was conducted in
normal sleepers with zolpidem intake early in the
morningsubsequenttoafullnight’ssleep.Althoughin
this study, no direct comparison was included with
zolpidem 5 or 10mg in standard oral formulations,
published observations of very similar study design
indicate that following the 10mg zolpidem dose,
measurable performance deﬁcit occurs at 1h post-
intake and is of similar magnitude as measured here
for the 3.5mg dose (Greenblatt et al., 1998). Thus, it
appears that sedative effects of ST zolpidem occurred
at a lower dose and at a time less than half of those
reported for oral zolpidem 10mg (Ambien
1 10mg).
Withinthe STzolpidemdoserangeinvestigatedinthis
study (1–3.5mg), there was a reasonable dose–effect
relationship with 3.5mg showing the greatest sedative
potential and 1.75mg as the lowest active dose. The
sublingual dose of 1mg can be considered a no-effect
ST zolpidem dose.
The PK proﬁle of ST zolpidem lozenges is
characterized by very rapid absorption with mean
peak concentrations of 17.8 (range 0–35.5), 32.2
(range 9.3–60.3), and 64.1 (range 19.9–125.9) ng/ml
for 1.0, 1.75, and 3.5mg of ST zolpidem, respectively,
occurring at approximately 37 (range 36–37.9)
minutes post-administration. In comparison, currently
available oral zolpidem tablets (Ambien
1) are
reported to attain peak concentrations (Cmax)o f5 9
(range 29–113) and 121 (range 58–272) ng/ml for 5
and 10mg, respectively, at a mean time (tmax) of 1.6h
for both (Ambien
1 Package Insert). Thus, tmax for ST
zolpidem occurs at a time less than half of that
reported of the oral zolpidem tablets.
In addition, within 20min post-dose, ST zolpidem
1.75 and 3.5mg achieved plasma zolpidem levels
greater than 20 to 25ng/ml, the estimated levels for
onset and offset of sedation (Patat et al., 1994). These
reportedly clinically relevant zolpidem blood levels
are paralleled by the PD observations of sedative
activity, speciﬁcally the effects on DSST scores and
subjective ratings of sedation. ST zolpidem did not
alter the elimination half-life of zolpidem: t1/2 of ST
zolpidem (2.3, 2.4, and 2.5h for 1, 1.75, and 3.5mg,
respectively) is very much in agreement with that
reported for oral zolpidem tablets (2.5 and 2.6h for 5
and 10mg, respectively).
ST zolpidem lozenges were found to be generally
safe and well tolerated. The side effect proﬁle was
consistent with the low-dose sedative-hypnotic effects
of zolpidem.
Taken together, these results suggest that ST
zolpidem 3.5mg produced sedative activity similar
to the sedative effects reported for 10mg oral
zolpidem. Furthermore, the maximal sedative effect
as measured by DSST produced peak by ST zolpidem
was observed as early as 20min post-dose as
compared to 60min post-dose reported for 10mg
oral zolpidem (Greenblatt et al., 1998). These PD
effects of ST zolpidem may be related to its PK as
suggested by a shorter tmax for ST zolpidem than that
reported for 10mg oral zolpidem. Lastly, ST zolpidem
produced rapid clinically relevant blood levels which
persisted for 2–4h which were paralleled with PD
assays sedativeactivity.Itmay beconcluded thatthese
characteristics make ST zolpidem an ideal candidate
for the prn treatment of sleep maintenance insomnia
characterized by prolonged wakefulness after mid-
dle-of-the-night awakenings.
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